Bisphosphonate related osteonecrosis of the maxilla – A case report
Abstract
Introduction. Bisphosphonates are a group of medications which have an important role in the treatment of some bone diseases. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of intravenous bisphosphonate therapy. The mechanism of action by which they may cause osteonecrosis is questionable. BRONJ is defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS) and classified into four stages (0-3). Treatment of BRONJ depends on the stage of disease and includes conservative treatment (stage 0 and 1) and surgical treatment (surgical debridement in stage 2 and sequestrectomy in stage 3). Case report. We presented a patient who had breast cancer, with stage 3 of bisphosphonate-related osteonecrosis of the upper jaw after zoledronic acid therapy for diffuse metastasis of the vertebrae. Before the treatment with zoledronic acid the patient was treated by a dentist. The osteonecrosis of the upper jaw started a year and a half after the start of zoledronic acid therapy and after tooth 24 extraction. She was treated by an oral surgeon at the beginning according to the protocol of AAOMS. The patient was sent to a maxillofacial surgeon due to the disease progression, and after computed tomography (CT) examination resection of the upper jaw was done. Conclusion. BRONJ is a condition with the specific clinical presentation, and it can be very serious for the patient, therefore it is necessary to emphasize the importance of screening. The doctors in different specialties (oncologist, dentist, oral surgeon and maxillofacial surgeon) must cooperate and control the patients under treatment with bisphosphonates before the therapy starts, as well as during and after it, in order to prevent, recognize on time and treat properly this complication.
References
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) in-duced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115−7.
Ruggiero SL, Mehrota B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527−34.
Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 2009; 45(7): 551−4.
Reid IR, Cornich J. Epidemiology and pathogenesis of osteone-crosis of the jaw. Nat Rev Reumatol 2011; 8(2): 90−6.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteone-crosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl): 2−12.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239−45.
Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, et al. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2012; 34(2): 194−200.
Agrillo A, Filiaci F, Ramieri V, Riccardi E, Quarato D, Rinna C, et al. Bisphosphonate-related osteonecrosis of the jaw(BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 2012; 16(12): 1741−7.
Bucur A, Nita T, Dinca O, Vladan C, Bucur MD. A case series of osteoporosis patients affected by bisphosphonate-related osteonecrosis of the jaws. Acta Endocrinol (Buc) 2011; 7(4): 483−90.
Tardast A, Sjöman R, Loes S, Abtahi J. Bisphosphonate associat-ed osteomyelitis of the jaw in patients with bony exposure: Prevention, a new way of thinking. J Appl Oral Sci 2015; 23(3): 310−14.
Borgiolo A, Viviani C, Duvina M, Brancato L, Spinelli G, Brandi ML, et al. Bisphosphonates-related osteonecrosis of the jaw: clinical and physiopathological consideration. Therap Clin Risk Manag 2009; 5: 217−27.
Loncarevic S, Brajkovic D, Vukomanovic-Djurdjevic B, Kanjevac T, Vasovic M. Bilateral numb chin syndrome as a symptom of breast cancer metastasis in the mandible: A case report and discussion on the usefulness of cone-beam computed tomog-raphy to assess bone involvement in oral cancer. Oral Radiol-ogy 2015: 1−7.
Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67(5 Suppl): 85−95.
Mücke T, Haarmann S, Wolff K, Hölzle F. Bisphosphonate relat-ed osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Cranio-maxillofac Surg 2009; 37(5): 291−7.
Filleul O, Crompot E, Saussez S. Bisphosphonate-induced oste-onecrosis of the jaw: a review of 2400 patient cases. J Cancer Res Clin Oncol 2010; 136(8): 1117−2416.
Pautke C, Otto S, Reu S, Kolk A, Ehrenfeld M, Stürzenbaum S, et al. Bisphosphonate related osteonecrosis of the jaw: manifesta-tion in a microvascular iliac bone flap. Oral Oncol 2011; 47(5): 425−9.